ArticleJournal of neurovirology2020
Clinical spectrum and prognosis of neurological complications of reactivated varicella-zoster infection: the role of immunosuppression.
Article in Journal of neurovirology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- New Insights Into the Therapeutic Management of Varicella Zoster Virus Meningitis: A Series of 123 Polymerase Chain Reaction-Confirmed Cases.Open forum infectious diseases · 2024Trial
- Prognostic Factors and Clinical Characteristics of Varicella Zoster Virus Meningitis: Impact of Treatment Delay and Age-Related Differences in a Japanese Tertiary Hospital.Neurology international · 2026Article
- Varicella-zoster virus-associated central nervous system infection in immunocompromised vs. immunocompetent herpes zoster patients: a comparative study.Frontiers in immunology · 2026Article
- Varicella-Zoster Myelitis With Thoracic Demyelination and Lumbosacral Plexopathy in the Setting of Uncontrolled HIV.Cureus · 2025Article
- Predictive value of blood routine-derived inflammation indexes for varicella-zoster virus meningitis in patients with acute herpes zoster.Frontiers in cellular and infection microbiology · 2025Article
- Clinical characteristics of varicella-zoster virus central nervous system infection in 108 unimmunocompromised patients.Frontiers in neurology · 2025Article
- [Zoster vaccination].Innere Medizin (Heidelberg, Germany) · 2024Article
- Article
- Immune changes and their relationship with prognosis in patients with varicella-zoster virus encephalitis/meningitis.American journal of translational research · 2023Article
- Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? A narrative review.Frontiers in neurology · 2023Review
- Factors Predictive of Varicella Zoster Virus Encephalitis/Meningitis: A Single-Center, Retrospective Study.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Article
- Flavonoids Target Human Herpesviruses That Infect the Nervous System: Mechanisms of Action and Therapeutic Insights.Viruses · 2022Review
- Neurological complications of varicella zoster virus reactivation: Prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid.Brain and behavior · 2022Article
- Meningitis/meningoencephalitis caused by varicella zoster virus reactivation: a retrospective single-center case series study.American journal of translational research · 2022Article
- Ramsay Hunt Syndrome Presenting as Acute Unilateral Combined Peripheral and Central Vestibulopathies.Journal of clinical neurology (Seoul, Korea) · 2022Article
- Recent Issues in Varicella-Zoster Virus Latency.Viruses · 2021Review
- Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.Muscle & nerve · 2021Article
- Identifying CNS infections in transplantation and immunomodulatory therapy.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunosuppressed patients are at higher risk for developing herpes zoster (HZ), and neurological complications are frequent in them. However, the influence of immunosuppression (IS) on the severity and prognosis of neurological complications of varicella-zoster virus (VZV) reactivation is unknown. We studied retrospectively patients with neurological complications due to VZV reactivation who attended our hospital between 2004 and 2019. We aimed to assess the clinical spectrum, potential prognostic factors, and the influence of the immune status on the severity of neurological symptoms. A total of 98 patients were included (40% had IS). Fifty-five patients (56%) had cranial neuropathies which included Ramsay-Hunt syndrome (36 patients) and cranial multineuritis (23 patients). Twenty-one patients developed encephalitis (21%). Other diagnosis included radiculopathies, meningitis, vasculitis, or myelitis (15, 10, 6, and 4 patients, respectively). Mortality was low (3%). At follow-up, 24% of patients had persistent symptoms although these were usually mild. IS was associated with severity (defined as a modified Rankin scale greater than 2) (odds ratio, 4.23; 95% confidence interval, 1.74-10.27), but not with prognosis. Shorter latency between HZ and neurologic symptoms was the only factor associated with an unfavorable course (death or sequelae) (odds ratio, 0.82; 95% confidence interval, 0.71-0.95). In conclusion, the clinical spectrum of neurological complications in VZV reactivation is wide. Mortality was low and sequelae were mild. The presence of IS may play a role on the severity of neurological symptoms, and a shorter time between HZ and the onset of neurological symptoms appears to be a negative prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.